Novo Nordisk sues Eli Lilly over weight-loss drug ads

Novo Nordisk, a Danish drug company, has sued Eli Lilly, an American drug company, in a US court.

Novo says Eli Lilly's ads for their weight-loss and diabetes drugs are misleading.

Novo claims that Eli Lilly compares their drugs to lower doses of Novo's drugs, making them seem more effective.

Novo wants the court to stop these ads and make Eli Lilly run new ads to correct the misleading information.

Both companies are competing in the growing market for weight-loss drugs, which is expected to be worth $120 billion by 2030.

Novo says that higher doses of their drugs show similar weight loss results to Eli Lilly's drugs, but Eli Lilly's ads don't mention this.

Novo also says that Eli Lilly's ads for their diabetes drug Mounjaro incorrectly compare it to an older, lower dose of Novo's drug Ozempic.